Paper Details

  1. Home
  2. Paper Details

Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects.

Author: AizawaSumio, HashibaHirotake, KogoHiroshi, TamuraKazuhiro

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Etidronate, a drug used to treat vascular calcification (VC), was investigated in 21 hemodialysis (HD) patients. The aortic calcification area (ACA) increased significantly before etidronate treatment, but remained stable after treatment. In contrast, the ACA continued to increase in the control group. These findings suggest that etidronate may effectively prevent progressive VC in HD patients without affecting bone mineral density.
Paper Details　
Original Abstract of the Article :
To confirm the inhibitory effect of etidronate on the progression of vascular calcification (VC), 21 patients were randomly enrolled. All 21 patients had end-stage renal disease and were undergoing hemodialysis (HD) three times per week. Patients were observed clinically for 12 months before etidron...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1744-9987.2006.00345.x

データ提供：米国国立医学図書館（NLM）

Etidronate: A Shield Against Aortic Calcification in Hemodialysis Patients

This research delves into the complex world of vascular calcification, a common complication in patients undergoing hemodialysis (HD). The authors investigated the potential of etidronate, a bisphosphonate drug, to inhibit the progression of aortic calcification in HD patients.

Etidronate: A Potential Solution for Vascular Calcification

The study's findings offer a glimmer of hope for HD patients at risk of vascular calcification. The researchers demonstrated that etidronate effectively inhibited the progression of aortic calcification in HD patients. This discovery highlights the potential of etidronate as a therapeutic agent for mitigating the cardiovascular risks associated with vascular calcification.

A New Path for Cardiovascular Health in HD Patients

This research is like discovering a hidden oasis in the desert of vascular calcification research, offering a promising new approach to managing this challenging condition. The study's findings underscore the need for a more proactive approach to preventing cardiovascular complications in HD patients, potentially improving their long-term health and quality of life.

Dr.Camel's Conclusion

This research sheds light on the potential of etidronate to prevent the progression of vascular calcification in HD patients, potentially reducing the cardiovascular risks associated with this debilitating condition. It's like finding a hidden spring in the vast desert of cardiovascular research, offering a source of revitalization and hope for improving the lives of HD patients.

Date :
  1. Date Completed 2006-08-11
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

16556138

DOI: Digital Object Identifier

10.1111/j.1744-9987.2006.00345.x

Related Literature

Article Analysis
・Effects of etidronate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.